Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

“Just to be a thousand per cent clear,” says the first cricketer to link up with a website better known for pornography than ...

Generative & Agentic AI in healthcare demands robust data governance: Kodeeswaran Natarajan: Nandita Vijayasimha, Bengaluru Saturday, August 9, 2025, 08:00 Hrs [IST] The use of Ge ...

How does your 401(k) compare to the average worker's? Is it time to buy small-cap stocks? What you should do with any "raise" ...

Experience Groundbreaking Sleep and Cellular Support Backed by Terahertz Innovation, Trusted by Wellness Experts in 2025New ...

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First ...

Chief financial officer Karsten Munk Knudsen said that the pharma giant's cash channel was key to regaining market share and ...

After years of craving top-level cricket, getting a surfeit of the stuff in the recent while has convinced Proteas’ ...

Supreme Court holds balance sheet debt entry valid under Section 18 Limitation Act; excludes COVID period; remands IBC case to NCLT for ...

On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and ...